

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

666 Fifth Avenue
New York, New York 10103-3198
FAX: (212) 318-3400

FACSIMILE COVER SHEET

PLEASE TRANSMIT THE FOLLOWING PAGES TO:

NAME: Examiner P. GambleCOMPANY/FIRM
(LOCATION): U.S. Patent and Trademark OfficeFACSIMILE (703) 305-7401VOICE PHONE: (703) 308-3997

From:	<u>Norman D. Hanson</u>	Phone No.:	<u>212-318-3168</u>	Number of Pages Sent:	<u>5</u>
				(Including Cover Sheet)	
Date:	<u>November 13, 2000</u>	User No.:	<u>01030</u>	Flr:	<u>24</u>
				Matter No.:	<u>09885911</u>
Return Transmitted Fax To: <u>Annette Crossan</u>				Internet:	<u>nhanson@fulbright.com</u>

Re: LUD-5253.5-DIV

REMARKS:

If you experience problems with this transmission or have questions, please call 212-318-3250.

CONFIDENTIALITY NOTICE: Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify the sender by telephone and return the original message to Fulbright & Jaworski L.L.P. at the above address via the U.S. Postal Service at our expense. Thank you.

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is by facsimile transmitted to the Commissioner of Patents and Trademarks, Washington, D.C. 20231, on November 13, 2000.

FULBRIGHT & JAWORSKI L.L.P.

By

Annette Crossan

FD 5253.5 DIV (09885911)

35/T

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Thierry BOON-FALLEUR et al.

Serial No. : 08/819,669 OFFICIAL

Filed : March 17, 1997 11/13/00
PAUL AMER

For : TUMOR REJECTION ANTIGEN PRECURSORS,
TUMOR REJECTION ANTIGENS AND USES
THEREOF

Art Unit : 1644

Examiner : P. Gamble

November 13, 2000

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

AMENDMENT
UNDER 37
CFR § 1.116

This amendment is responsive to the office action dated September 26, 2000. Please amend applications as follows:

IN THE SPECIFICATION

Page 27, next to last line: change "Balb/C" to - - BALB/c - -

Page 28, line 3: change "BALB/C" to - - BALB/c - -

IN THE CLAIMS

Amend claim 176 as follows:

Claim 176 (amended)

The isolated tumor rejection antigen precursor of claim 174, wherein said tumor rejection antigen precursor is encoded by a nucleic acid molecule, the complementary nucleotide sequence of which hybridizes to SEQ ID NO: 8 [, under stringent conditions] at 0.1XSSC, 0.1% SDS.

OK TO
ENTER
175
3/26/01

T1